Wockhardt Share Price Target From 2025 to 2030: Wockhardt Limited is a well-known Indian biotech company and pharmaceutical company with global operations in numerous countries. It is engaged in research and development and pharma manufacturing of pharmaceutical formulation, active pharmaceutical ingredients (APIs), and vaccines. Focusing especially on innovation and global healthcare, Wockhardt has adequate presence within the pharma markets of India, the United Kingdom, the United States of America, and other countries.
Here we are comparing Wockhardt share price targets for 2025 and 2030 on technicals, financials, and industry trends.
Current Market Performance For Wockhardt Share Price
- Open Price: ₹1,405.00
- High Price: ₹1,428.80
- Low Price: ₹1,364.70
- Market Cap: ₹22.49K Cr
- P/E Ratio: Not Available (Due to Negative Earnings)
- Dividend Yield: 0.00%
- 52-Week High: ₹1,679.90
- 52-Week Low: ₹421.00
- Previous Close: ₹1,436.50
- Volume: 5,46,691
- Total Traded Value: ₹75.61 Cr
Shareholding Pattern For Wockhardt Share Price
- Promoters: 49.09%
- Retail & Others: 34.55%
- Mutual Funds: 7.13%
- Foreign Institutions (FIIs): 6.54%
- Other Domestic Institutions: 2.69%
Shareholding Changes For Wockhardt Share Price
- Promoters pledged 16.66% shares in the fourth quarter.
- Total pledge is 16.98% of promoter holding.
- Mutual funds increased holdings from 2.95% to 7.13%.
- Institutional investors increased holdings from 11.80% to 16.38%.
Technical Analysis For Wockhardt Share Price
- Momentum Score: 60.0 (Neutral)
- MACD (12, 26, 9): 32.8 (Above center line but below signal line)
- ADX: 18.3 (Weak trend strength)
- RSI (14): 48.2 (Neutral, neither oversold nor overbought)
- MFI: 65.1 (Slightly bullish, but not overbought)
- ROC (21): 5.0 (Uptrend in short term)
- ROC (125): 45.9 (Strong long-term momentum)
- ATR: 90.1 (High volatility stock)
Analysis For Wockhardt Share Price
- Stock is neutral trend, and there are signs of moderate bullish momentum.
- Medium and long-term indicators indicate positive direction.
- Higher institutional investment is a reflection of increased confidence in Wockhardt growth story.
Wockhardt Share Price Target for 2025 to 2030
| YEAR | TARGET PRICE (₹) |
| 2025 | ₹1700 |
| 2026 | ₹2900 |
| 2027 | ₹4100 |
| 2028 | ₹5300 |
| 2029 | ₹6500 |
| 2030 | ₹7700 |
Factors Influencing Growth For Wockhardt Share Price
- Wockhardt expansion in global markets: Wockhardt is consolidating its base in UK, US, and EU pharma markets.
- New Drug Approvals: New drug approvals in the vaccine and antibiotic segment can contribute to topline growth.
- Debt Reduction: Debt reduction of financial debt by debt settlement can enhance investors’ trust.
- Increased Institutional Investment: Mutual Funds and FIIs are optimistic again regarding Wockhardt, indicating long-term value.
- Industry Growth: Indian pharma sector would grow at the rate of CAGR 10-12% during the next decade.
Company Information
About Wockhardt
Wockhardt Ltd. is an Indian multinational pharmaceutical and biotech company headquartered in Mumbai with operations in more than 20 countries and several R&D facilities across the globe.
Key Highlights
- Started: 1967
- Head Office: Mumbai, India
- Business Segments: Pharmaceuticals, Biotech, Vaccines, APIs
- Geographic Presence: India, US, UK, Europe, Africa, and South-East Asia
- Key Area: Antibiotics, Vaccines, Specialty Pharmaceuticals
Frequently Asked Questions (FAQs) For Wockhardt Share Price
1. What is the long-term future of Wockhardt shares?
Wockhardt will be watched to grow exponentially from 2025 to 2030 to a vision of ₹7,700 in 2030. It is due to growth overseas, introduction of new medicines, and growing investor confidence.
2. Is Wockhardt an investment for the future?
Wockhardt is a high-risk, high-gain stock. Though it has been displaying high growth possibilities, investors should not forget its volatility and financial risks.
3. What are Wockhardt’s investment risks?
- High debt ratio (1.17), reflecting financial leverage.
- Negative Return on Equity (ROE) (-13.03%), reflecting past financial problems.
- Regulatory risks via drug approvals and compliance.
- Stock price with excessive volatility.
4. Will Wockhardt pay dividends in the future?
Wockhardt’s 0.00% dividend yield, i.e., zero dividend is paid. But as soon as funds are available, payment of dividend can be made in future.
5. What is driving Wockhardt’s growth potential?
- Growth of emerging markets.
- Increased emphasis on R&D and innovation.
- Biotech and specialty pharma leadership.
- Higher vaccine and antibiotic usage.
6. Why is Wockhardt unique among pharma stocks?
Wockhardt is a very volatile but growth-oriented pharma stock. Although Dr. Reddy’s or Sun Pharma never had financial troubles in the past, Wockhardt had some but is now turning the corner with new investment and market penetration. Wockhardt will increase seriously between 2030 and 2025, as also the target price of ₹7,700 by 2030. Whereas if the company has had its own share of financial issues, institutional investor hopes, growth, and innovation are a rosy future ahead. Investors are cautioned, however, for volatility risks are high, regulatory risks, and finances before investing in any decision.
